FFA
GILD icon

Freedman Financial Associates’s Gilead Sciences GILD Stock Holding History

Freedman Financial Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-635
Closed -$39K – 159
2022
Q1 		$39K Hold
635
– – 0.03% 232
2021
Q4 		$46K Hold
635
– – 0.03% 214
2021
Q3 		$44K Hold
635
– – 0.03% 211
2021
Q2 		$44K Sell
635
-500
-44% -$33.4K 0.03% 208
2021
Q1 		$73K Hold
1,135
– – 0.06% 140
2020
Q4 		$66K Buy
+1,135
New +$68.5K 0.06% 143

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Freedman Financial Associates's GILD Position: Q2 2022 in Review

Freedman Financial Associates sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 635 shares — an estimated $39K sold.

Freedman Financial Associates first reported a position in GILD in Q4 2020 and held it in 6 quarters. The position peaked at $73K in Q1 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

  • Freedman Financial Associates reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 635 Gilead Sciences shares in Q2 2022, an estimated $39K.
  • Freedman Financial Associates first reported a position in Gilead Sciences in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's Gilead Sciences position peaked at $73K in Q1 2021.
  • 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.